Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This review reports on new and effective drug developments for treating severe alopecia areata, including oral baricitinib, but emphasizes that no treatment guarantees permanent remission or works for all patients, with high recurrence rates after stopping medication.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

JAK inhibitors might help treat alopecia areata.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.